ArticleSurgery today2018
Human CD200 suppresses macrophage-mediated xenogeneic cytotoxicity and phagocytosis.
Article in Surgery today, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 29 citations in OpenAlex.
- Progress in immunological research on innate effectors in xenotransplantation.Surgery today · 2026Review
- Complement system in kidney transplantation: from innate immune surveillance to a therapeutic and genetic engineering target.Frontiers in immunology · 2026Review
- Immunometabolism of Liver Xenotransplantation and Prospective Solutions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Human pluripotent stem cell-derived hepatic progenitors exhibit a partially hypoimmunogenic phenotype and actively inhibit immune responses.Frontiers in immunology · 2025Article
- How should cardiac xenotransplantation be initiated in Japan?Surgery today · 2024Review
- Suppression of xenogeneic innate immune response by a membrane-type human surfactant protein-A.Experimental and therapeutic medicine · 2022Article
- Genetic engineering of pigs for xenotransplantation to overcome immune rejection and physiological incompatibilities: The first clinical steps.Frontiers in immunology · 2022Review
- Aspects of the Complement System in New Era of Xenotransplantation.Frontiers in immunology · 2022Review
- The Innate Cellular Immune Response in Xenotransplantation.Frontiers in immunology · 2022Review
- The Phagocytic Code Regulating Phagocytosis of Mammalian Cells.Frontiers in immunology · 2021Review
- Pre-transplant CD200 and CD200R1 concentrations are associated with post-transplant events in kidney transplant recipients.Medicine · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeVarious strategies, such as the generation of alpha-1,3-galactosyltransferase knocked-out pigs and CD55 transgenic pigs, have been investigated to inhibit pig to human xenogeneic rejection. Our aim is to develop strategies to overcome the hurdle of not only hyper acute rejection, but also that of cellular xenogeneic rejection (CXR). Although macrophages have been well known to play a critical role in CXR, monocyte/macrophage-mediated xenogeneic rejection has not been well studied. In this study, we evaluated the effect of CD200 in xenogeneic rejection by macrophages.
methodsNaïve swine endothelial cells (SEC) and SEC/CD200 were co-cultured with M0 macrophages and the cytotoxicity was measured by a WST-8 assay. The phagocytosis of SEC and SEC/CD200 by macrophages was analyzed by flow cytometry.
resultsWhile CD200 failed to suppress a significant amount of cytotoxicity against SEC by monocytes, M0 macrophage-mediated cytotoxicity was significantly suppressed by human CD200. The phagocytosis by M0 macrophages was also tested. The phagocytosis assay revealed that human CD200 suppresses M0 macrophage-mediated phagocytosis.
conclusionsOur findings indicate that human CD200 suppresses the xenogeneic rejection by CD200R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.